Sponsor Study ID:
A PHASE 1B/2 STUDY OF AVB S6 500 IN COMBINATION WITH CABOZANTINIB, AVB S6 500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB S6 500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
(MUSC NetID required for document access)